Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRLHR | P49683 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL434965 | 0.99 | PRLHR (1.00) | PRLHR | |
| SCHEMBL436955 | 0.89 | PRLHR (1.00) | PRLHR | |
| Hydrochloric Acid SCHEMBL450170 | 0.88 | PRLHR (0.88) | PRLHR | |
| Hydrochloric Acid SCHEMBL450296 | 0.87 | PRLHR (1.00) | PRLHR | |
| SCHEMBL434962 | 0.87 | PRLHR (0.88) | PRLHR | |
| SCHEMBL437434 | 0.87 | PRLHR (0.88) | PRLHR | |
| SCHEMBL435859 | 0.86 | PRLHR (1.00) | PRLHR | |
| Hydrochloric Acid SCHEMBL447186 | 0.86 | PRLHR (1.00) | PRLHR | |
| Hydrochloric Acid SCHEMBL453287 | 0.86 | PRLHR (0.99) | PRLHR | |
| SCHEMBL435913 | 0.85 | PRLHR (1.00) | PRLHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4144351-A1 | HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVES AS INHIBITORS OF THE PROSTAGLANDIN F RECEPTOR | ObsEva S.A. (CH) | 2023-03-08 | — | — | EP | disclosed |
| EP-4140988-A1 | L-VALINATE OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF | Merck Serono S.A. (CH) | 2023-03-01 | — | — | EP | disclosed |
| EP-3397622-B1 | CO-ADMINISTRATION OF ALPHA-AMINO ESTER OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND A TOCOLYTIC AGENT | ObsEva SA (CH) | 2022-03-09 | — | — | EP | disclosed |
| EP-3400217-B1 | L-VALINATE OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE, ITS SALT AND CRYSTAL FORM THEREOF | MERCK SERONO SA (CH) | 2022-03-09 | — | — | EP | disclosed |
| US-20210323935-A1 | ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF | MERCK SERONO S.A. (CH) | 2021-10-21 | — | — | US | disclosed |
| US-10995132-B2 | Optimal interstrand bridge for collagen mimics | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2021-05-04 | — | — | US | disclosed |
| US-10555934-B2 | Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof | ObsEva S.A. (CH) | 2020-02-11 | — | — | US | disclosed |
| US-20190194151-A1 | ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF | MERCK SERONO S.A. (CH) | 2019-06-27 | — | — | US | disclosed |
| US-20190119355-A1 | Optimal Interstrand Bridge for Collagen Mimics | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-04-25 | — | — | US | disclosed |
| US-10259795-B2 | Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof | MERCK SERONO S.A. (CH) | 2019-04-16 | — | — | US | disclosed |
| EP-0547706-A1 | Image intensification chemistry with blocked incorporated developers | EASTMAN KODAK COMPANY (US) | 1993-06-23 | — | — | EP | disclosed |
| US-5210007-A | Color photographic film for latent silver images and deblocking by reaction with dinucleophile reagent | EASTMAN KODAK COMPANY (US) | 1993-05-11 | — | — | US | disclosed |
| US-5037975-A | Antibiotics | ELI LILLY AND COMPANY (US) | 1991-08-06 | — | — | US | disclosed |
| US-4994486-A | Neurological disorders | ABBOTT LABORATORIES (US) | 1991-02-19 | — | — | US | disclosed |
| US-4963568-A | TREATMENT OF PARKINSON*S DISEASE, CARDIOVASCULAR DISORDERS | ABBOTT LABORATORIES (US) | 1990-10-16 | — | — | US | disclosed |
| US-4939249-A | HEATING CEPHALOSPORIN 1,1-DIOXIDE IN SOLVENT WITH FREE RADICAL INITIATOR | ELI LILLY AND COMPANY (US) | 1990-07-03 | — | — | US | disclosed |
| EP-0359540-A2 | Process for 1-carba(dethia) cephalosporins | ELI LILLY AND COMPANY (US) | 1990-03-21 | — | — | EP | disclosed |
| US-4703118-A | Synthesis of 3-iodomethyl cephalosporins | ELI LILLY AND COMPANY (US) | 1987-10-27 | — | — | US | disclosed |
| US-4297350-A | ORAL ANTIFERTILITY AGENTS; REVERSIBLE | THE UPJOHN COMPANY (US) | 1981-10-27 | — | — | US | disclosed |
| US-4183923-A | 3-ALKANESULFONYLOXYAZETIDINES | SCHERING CORPORATION (US) | 1980-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194151-A1 | ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF | PGF, PTGER1, PTGFR | PRLHR 59/4885 |
| US-10259795-B2 | Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof | PGF, PTGER1, PTGFR | PRLHR 64/4885 |
| US-20190119355-A1 | Optimal Interstrand Bridge for Collagen Mimics | COL14A1, COL1A1, COL2A1 | PRLHR 3519/4885 |
| US-20210323935-A1 | ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF | PGF, PTGER1, PTGFR | PRLHR 59/4885 |
| US-10995132-B2 | Optimal interstrand bridge for collagen mimics | COL14A1, COL1A1, COL2A1 | PRLHR 3519/4885 |
| US-10555934-B2 | Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof | PGF, PTGER1, PTGER2 | PRLHR 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.